Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswir

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (th

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight an

Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Con

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst cons

On track for regulatory submission of MGX-001 to advance global clinical program, including investig

Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) has earned a consensus recommendation of "Moderate

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing compan

Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary C

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim

Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the

Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Mo

Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.6 per share versus the Zacks Cons

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity i

Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcri

EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (t

MGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks Transcript

HIAB CORPORATION, PRESS RELEASE, 9 FEBRUARY 2026 AT 3:00 PM (EET) Hiab expands US footprint with app

Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) shares dropped 1.2% during trading on Monday. The s

MGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks Transcript

New name reflects the Company's strategic evolution focused on later-stage preclinical assets le

New name reflects the Company's strategic evolution focused on later-stage preclinical assets levera

Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been assigned an average rating of "

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 202

Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizin

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.55) per share which beat the analyst consen

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers t

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the

OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block Open

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers t

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the

Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central ne

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.68) per share which missed the analyst cons

HC Wainwright & Co. analyst Mitchell Kapoor maintains Metagenomi (NASDAQ:MGX) with a Buy and

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the

HC Wainwright & Co. analyst Mitchell Kapoor maintains Metagenomi (NASDAQ:MGX) with a Buy and

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primat